Ergoteles’s Janux Therapeutics JANX Stock Holding History

Ergoteles’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-31,563	Closed	-$416K	–	1495
2022 Q4	$416K	Buy	+31,563	New	+$462K	0.02%	777

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ergoteles's JANX Position: Q1 2023 in Review

Ergoteles sold out of Janux Therapeutics (JANX) in Q1 2023, closing a stake of 31,563 shares — an estimated $416K sold.

Ergoteles first reported a position in JANX in Q4 2022 and held it in 1 quarter. The position peaked at $416K in Q4 2022. 48 funds tracked by Wall St. Rank hold JANX as of Q1 2023.

Ergoteles reported no remaining Janux Therapeutics position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 31,563 Janux Therapeutics shares in Q1 2023, an estimated $416K.
Ergoteles first reported a position in Janux Therapeutics in Q4 2022 and held it in 1 quarter.
Ergoteles's Janux Therapeutics position peaked at $416K in Q4 2022.
48 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.